Key facts
- This page summarizes Robert Kramer's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 4 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 02 Mar 2022, 18:25.
Robert Kramer - 28 Feb 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Signature
- /s/ S. Scott Lieberman, Attorney-in-fact
- Issuer symbol
- EBS
- Transactions as of
- 28 Feb 2022
- Net transactions value
- +$5,531,973
- Form type
- 4
- Filing time
- 02 Mar 2022, 18:25:49 UTC
- Previous filing
- 25 Feb 2022
- Next filing
- 10 Feb 2023
- SEC
- View on sec.gov
Key filing fact
Robert Kramer filed Form 4 for Emergent BioSolutions Inc. (EBS) on 02 Mar 2022.
Change
- Previous filing in this sequence was filed on 25 Feb 2022.
- Current net transaction value: +$5,531,973.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
EBS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +33,833
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 193,102
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
EBS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +55,582
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 248,684
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
EBS
transaction
Common Stock
Tax liability
- Transaction value
- $67,983
- Shares
- -1,715
- Change %
- -0.69%
- Price
- $39.64
- Shares after
- 246,969
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F3
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
EBS
transaction
Derivative
Employee Stock Options (Right to Buy)
Award
- Transaction value
- $5,599,955
- Shares
- +135,330
- Change %
- Price
- $41.38
- Shares after
- 135,330
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 135,330
- Exercise price
- $41.38
- Footnotes
- F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
| F2 | Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| F3 | Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. |
| F4 | Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |